[11C]LY-2795050

N/A

Report date: 2025/11/20 17:57:01
NME

Base Information

Drug Name[11C]LY-2795050
Drug Alias NameLY-279505011C-LY-2795050[11C]LY-2795050[11C]PKAB
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentSmall molecules > Heterocyclic drugs +[5] 
Mechanisms of ActionKappa opioid receptor antagonists
TargetsKappa opioid receptor
Therapy Area/IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorOpioid-Related Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesCerevel Therapeutics LlcEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorOpioid-Related Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A